Importantly, these CRC gene signatures are consistent across human NBL tumors (mesenchymal in low risk and adrenergic in high risk) and LMO3, an LMO1 paralog, can sometimes substitute for LMO1 and drive the more aggressive adrenergic CRC program. This evidence concerns the gene LMO1 and colorectal carcinoma.